Next Phase of Pharma Growth: Generics 11.21.22 // Michael McTague The industry is also undergoing rapid expansion in specialty medications.
Pharma M&A Shows an Industry Looking to Specialize Two of the biggest acquisitions in the industry confirm a trend in pharma M&A: The big players are trawling for opportunities in the rare-disease space.
Telehealth / Telemedicine: A Sector With More Than a Pulse The industry foresees CAGRs ranging from 19% to 24% to 32%. But patient attitudes change slowly.
Government May Have No Conscience. But Sometimes It Has a Policy. In pharma, the future heuristic will be: blockbuster or nothing!
BridgeBio Pharma Inks Licensing Deal With Bristol Myers Squibb Worth up to $905 Million BMY will pay BBIO $90 million in upfront cash.
AbbVie and Teva Weighing $5 Billion Opioid Lawsuit Settlement The companies are facing over 3,500 opioid-related lawsuits.
Bausch + Lomb Raises $630 Million in IPO, Missing Expectations The stock was priced at $18 per share, off a filing range of $21 - $24.
An Easy Way to Profit Off One of Today’s Strongest Sectors